Mangalam Drugs and Organics Ltd
Incorporated in 1977, Mangalam Drugs & Organics Ltd manufactures Active Pharmaceutical Ingredients and Intermediates.[1]
- Market Cap ₹ 48.3 Cr.
- Current Price ₹ 30.4
- High / Low ₹ 86.0 / 22.7
- Stock P/E
- Book Value ₹ 65.1
- Dividend Yield 0.00 %
- ROCE -14.3 %
- ROE -35.2 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.47 times its book value
Cons
- Company has low interest coverage ratio.
- Promoter holding is low: 35.6%
- Company has a low return on equity of -11.6% over last 3 years.
- Contingent liabilities of Rs.34.6 Cr.
- Debtor days have increased from 45.3 to 63.4 days.
- Promoter holding has decreased over last 3 years: -14.7%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|
| 369 | 318 | 232 | 232 | |
| 351 | 282 | 247 | 241 | |
| Operating Profit | 17 | 36 | -15 | -9 |
| OPM % | 4.7% | 11% | -6% | -3.9% |
| 0 | 0 | 1 | 0 | |
| Interest | 14 | 15 | 16 | 16 |
| Depreciation | 15 | 17 | 18 | 18 |
| Profit before tax | -11 | 5 | -49 | -42 |
| Tax % | -18% | -41% | -9% | |
| -9 | 7 | -44 | -38 | |
| EPS in Rs | -5.73 | 4.25 | -28.05 | -24.17 |
| Dividend Payout % | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -22% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -292% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -16% |
| 5 Years: | -26% |
| 3 Years: | -33% |
| 1 Year: | -63% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -12% |
| Last Year: | -35% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Equity Capital | 16 | 16 | 16 |
| Reserves | 120 | 133 | 87 |
| 107 | 96 | 105 | |
| 91 | 121 | 106 | |
| Total Liabilities | 334 | 366 | 315 |
| 148 | 163 | 159 | |
| CWIP | 8 | 3 | 0 |
| Investments | 0 | 0 | 0 |
| 178 | 201 | 156 | |
| Total Assets | 334 | 366 | 315 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| 4 | 43 | 4 | |
| -12 | -19 | -12 | |
| 5 | -22 | 6 | |
| Net Cash Flow | -3 | 1 | -2 |
| Free Cash Flow | -8 | 23 | -8 |
| CFO/OP | 23% | 118% | -30% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Debtor Days | 28 | 45 | 63 |
| Inventory Days | 185 | 303 | 239 |
| Days Payable | 99 | 199 | 177 |
| Cash Conversion Cycle | 113 | 149 | 126 |
| Working Capital Days | 11 | 5 | -65 |
| ROCE % | 8% | -14% |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Employees Count ・Standalone data |
|
|||||||||
| Export Turnover (Foreign Exchange Earned) INR Lakhs ・Standalone data |
||||||||||
| Anti-Malarial API Revenue Share % of total revenue ・Standalone data |
||||||||||
| Top Customer Concentration % of total revenue ・Standalone data |
||||||||||
| Total Production Volume Metric Tons (MT) ・Standalone data |
||||||||||
| R&D Scientists Count ・Standalone data |
||||||||||
| Installed Capacity Tonnes Per Annum (TPA) ・Standalone data |
||||||||||
| Tenofovir Disoproxil Fumarate Production Metric Tons (MT) ・Standalone data |
||||||||||
Extracted by Screener AI
Documents
Announcements
-
Defaults under Para A sub-paragraph 6 of Schedule III-Subsequent Disclosure
- Company defaulted on Bank of Maharashtra loan ₹951.19 lakh and Bank of Baroda loan ₹606.08 lakh since Oct 2025.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- Newspaper publication for declaration of Un-audited Financial Results (Standalone & Consolidated) for the quarter ended 30th June, 2026
-
Appointment Of Secretarial Auditor Of The Company For Term Of 5 Years Subject To Approval Of Shareholders In Ensuing 53Rd Annaul General Meeting Of The Company
- Board approved Q1 FY2026-27 results, appointed secretarial and statutory auditors for five years.
-
Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s
- Board approved Q1 FY2026-27 results and appointed secretarial and statutory auditors.
- Declaration Of Un-Audited Financial Results (Standalone & Consolidated) For The Quarter Ended 30Th June, 2026
Annual reports
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2013
from nse
-
Annual Report 2012
from nse
Business Overview:[1]
MDOL (formerly Advent Pharma Pvt Ltd) is a part of the Mangalam group. The co manufactures bulk drugs, and organic and inorganic chemicals. It is among the few companies which are World Health Org.approved Indian companies to be associated
with the William J Clinton Foundation (Clinton Foundation) for manufacture of anti-malarial drugs. MDOL supplies artemisinin-based bulk drugs to pharmaceutical companies, for the manufacture of anti-malarial formulations.